Clinical trials
Systemic Sclerosis clinical trials
Below are recruiting systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 176 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05149768RecruitingPhase 2
Study extension of Adcetris for worsening early skin sclerosis
This trial is a follow-up study that keeps studying Adcetris (brentuximab vedotin) in people with worsening diffuse cutaneous systemic sclerosis (dcSSc) who were in an earlier Adcetris study. It aims to see if the treatment continues to help your skin symptoms over time and stays safe.
London, OntarioAges 18 years+ - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Los Angeles, CaliforniaAges 18–70 - NCT06827977RecruitingPhase 2
Microbiome transplant for constipation and bloating in scleroderma
This study tests a microbiome transplant (friendly bacteria given as an enema or in capsules) to see if it helps with constipation and bloating in people with scleroderma. The goal is to improve digestive symptoms related to your condition.
Houston, TexasAges 18 years+ - NCT06646913RecruitingPhase 1
TENS therapy for bloating in scleroderma
This study tests whether a gentle electrical device placed on the skin (TENS) can help reduce bloating and belly discomfort in people with scleroderma. If you have scleroderma and struggle with daily bloating, this trial may offer a non-medication option to try.
Ann Arbor, MichiganAges 18 years+ - NCT06672822RecruitingPhase 2
STS injections for calcinosis in scleroderma
This trial tests if injecting a medication called STS directly into calcium deposits can relieve pain and symptoms. It may help patients with scleroderma or related conditions who have painful calcium lumps.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70 - NCT06894654Recruiting
Identifying skin regulation in scleroderma
This study compares skin samples from people with scleroderma and healthy volunteers to understand what goes wrong in the skin. It may help researchers find new treatment targets.
LeedsAges 18 years+ - NCT06947473RecruitingPhase 1/Phase 2
CAR T-cell therapy for lupus, sclerosis, and Sjogren's
This trial tests a new type of immune cell therapy (CAR T-cells from umbilical cord blood) for people with certain autoimmune diseases that haven't responded to standard treatments. It aims to see if targeting two proteins (CD19 and BCMA) can help calm the overactive immune system.
Beijing, Beijing MunicipalityAges 6–65 - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT07000682RecruitingEarly Phase 1
UTAA91 injection for systemic sclerosis study
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Wuhan, HubeiAges 18 years+ - NCT07167537RecruitingPhase 1
Study of OL-CD19-GDT for hard-to-treat autoimmune diseases
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
BeijingAges 18–65 - NCT07182981Recruiting
Chewing and swallowing in scleroderma patients
This study looks at how scleroderma affects chewing and swallowing in children and adults. It aims to help understand these problems better so care can be improved.
Çankaya, AnkaraAges 7 years+ - NCT07183072Recruiting
Scleroderma: Physical Performance and Functionality Study
This study looks at how scleroderma affects physical performance and daily function in children and adults. It aims to understand the impact of the disease on movement and everyday activities.
Çankaya, AnkaraAges 7 years+ - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07228429Recruiting
Measuring calcium deposits in scleroderma with CT scans
This study will use CT scans to measure calcium deposits under the skin in people with scleroderma. It may help doctors better understand and track this condition.
New Haven, ConnecticutAges 18 years+ - NCT07245238RecruitingPhase 3
CBD lotion for itching in scleroderma
This trial tests if a CBD (cannabidiol) lotion can help reduce itching in people with scleroderma, a condition that often causes chronic itch. It compares the CBD lotion to a placebo (inactive lotion) to see if it works and is safe.
Khon KaenAges 18–70 - NCT07284797RecruitingPhase 1
Safety study for autoimmune disease and healthy volunteers
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
MelbourneAges 18–75 - NCT07355972RecruitingEarly Phase 1
CT1195E cell therapy for progressive scleroderma
This trial tests a new cell therapy called CT1195E for people with refractory or progressive systemic sclerosis (scleroderma) that also affects the lungs. It aims to see if the treatment is safe and can help slow or stop the disease.
Wuhan, HubeiAges 18–60 - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT06472362Enrolling by invitation
Chest CT scans to predict lung disease in scleroderma
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
ParisAges 18–99 - NCT05493514Recruiting
Robotic training program for walking and balance
This trial studies whether a robotic training system (called G-EO) can help people with neurological conditions improve walking and balance. It may help by testing which factors predict who benefits most, and it requires regular training sessions.
MilanAges 18 years+
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis?
- Yes. Clin2 currently lists 176 recruiting systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.